Mark Goldstein, MD
Hematology & Oncology · Germantown, MDNPI 1649216342
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,268 of the $21,202 with a category attached, or 72.0%. 60 manufacturers reported payments, led by Tempus AI, Inc at 29.7% of the total. Reporting peaked in 2024 at $9,783 and has fallen 63.0% since, to $3,623 in 2025.
Across 581 payments — averaging $36.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tempus AI, Inc$6K
- AstraZeneca$1K
- Novartis$1K
- Johnson & Johnson$1K
- Merck$893
- Pfizer$633
- plus $9K from 54 others
Across 58 payments — averaging $11,073 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$147K
- Merck$98K
- Astrazeneca UK Limited$89K
- Aadi Bioscience, Inc.$87K
- Amgen$64K
- Pfizer$55K
- plus $102K from 3 others
What the payments were for
- Consulting fees$5,93528%
- Food & beverage$15,26872%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,202 in reported general payments places this provider in the 80th percentile of 242 hematology & oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 17 | $232,218 |
| CalquenceAcalabrutinib Maleate | 14 | $210,851 |
| JakafiRuxolitinib Phosphate | 11 | $190,086 |
| PromactaEltrombopag Olamine | 15 | $100,073 |
| Abiraterone Acetate | 13 | $72,604 |
| EliquisApixaban | 102 | $66,601 |
| XareltoRivaroxaban | 36 | $43,137 |
| Dexamethasone | 29 | $668 |
| Letrozole | 20 | $592 |
| Doxycycline Hyclate | 11 | $456 |
| Ondansetron OdtOndansetron | 14 | $337 |
| Hydroxyurea | 23 | $289 |
| Prednisone | 26 | $212 |
| Prochlorperazine Maleate | 16 | $209 |
| Ondansetron Hcl | 18 | $173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada, Xarelto | $1,213 | $275,35553 claims |
| AstraZenecaCalquence | $1,434 | $210,85114 claims |
| Incyte CorporationJakafi | $233 | $190,08611 claims |
| NovartisPromacta | $1,423 | $100,07315 claims |
| PfizerEliquis | $633 | $66,601102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 242 hematology & oncology providers in Maryland.
Other hematology & oncology in Germantown
- Ralph BocciaBethesda$3.1M
- Sandra SwainBethesda$1M
- Kashif AliSilver Spring$987K
- Ani BalmanoukianBaltimore$842K
- Benjamin LevyBaltimore$578K
- Patrick FordeBaltimore$269K
- Noah HahnBaltimore$133K
- Walid El AyassSalisbury$111K
- Arun BhandariAnnapolis$103K
- Huzefa BahrainBaltimore$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.